Beijing: Dark Horse Consulting Group ('DHCG'), a leader in biotherapeutics consulting, and KunTuo Medical Research and Development Co., Ltd. ('KunTuo'), a contract research organization specializing in clinical research services, have announced the signing of a Memorandum of Understanding (MOU). This strategic collaboration is designed to provide biotherapeutics developers with a comprehensive and integrated path to conducting clinical trials in China.

According to BERNAMA News Agency, the partnership leverages DHCG's expertise in areas such as regulatory compliance, CMC, nonclinical and clinical practices, quality assurance, supply chain logistics, commercial launching, and business analytics. This is combined with KunTuo's substantial clinical research knowledge and resources within China. KunTuo, founded by IQVIA to serve the Chinese market, upholds IQVIA's high standards in quality management and has delivered over 1,000 clinical research services to pharmaceutical and medical device companies both domestically and internationally since 2011. Through this collaboration, DHCG and KunTuo aim to provide client companies with an integrated approach from global regulatory strategies to local clinical execution.